$GNLX News

Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

Genelux Q2 EPS $(0.21) Misses $(0.19) Estimate

Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer

Genelux Announces Publication Of Translational And Clinical Findings From Phase 1b/2 VIRO-15 Trial Of Olvi-Vec-Primed Immunochemotherapy In Heavily Pretreated Patients With Platinum-R/R Ovarian Cancer

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

Benchmark Maintains Speculative Buy on Genelux, Lowers Price Target to $20

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Genelux Q4 EPS $(0.24) Misses $(0.21) Estimate

Genelux Corporation to Participate in Upcoming Conferences

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

Genelux shares are trading lower. The company announced the pricing of a public offering of 6.67 million common shares at a price of $3.00 per share.

Genelux shares are trading lower. The company announced the pricing of a public offering of 6.67 million common shares at a price of $3.00 per share.

Genelux Prices ~$20M Public Offering Of 6.67M Shares At A Price Of $3/Share

Genelux Corporation Announces Proposed Public Offering of Common Stock

Genelux Corporation Announces Proposed Public Offering Of Common Stock; No Terms Disclosed

Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials

Genelux Announces Interim Results From Two Ongoing Trials, Phase 1b/2 SCLC And Phase 2 VIRO-25, Evaluating Systemic Administration Of Olvi-Vec In Patients With Progressive SCLC And NSCLC

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer